Table 4. Multivariate analysis of risk factors of immune-related adverse events (irAEs). Combination therapy was an independent risk factor for immune thrombocytopenic purpura.
| Variable | ITP | Peripheral neuropathy | Dehydration | |||||
|---|---|---|---|---|---|---|---|---|
| Adjusted OR (95% CI) | P value | Adjusted OR (95% CI) | P value | Adjusted OR (95% CI) | P value | |||
| Combination therapy | 5.02 (2.11–11.94) | <0.001 | 1.66 (0.79–3.50) | 0.181 | 1.69 (0.80–3.57) | 0.166 | ||
| Comorbidity | 0.64 (0.20–2.04) | 0.448 | 0.83 (0.38–1.79) | 0.627 | 1.28 (0.70–2.35) | 0.420 | ||
| Disease Progression | 0.85 (0.33–2.18) | 0.376 | 0.83 (0.51–1.36) | 0.456 | 1.07 (0.70–1.63) | 0.762 | ||
| Stage IV | 0.86 (0.44–1.68) | 0.737 | 1.12 (0.60–2.09) | 0.722 | 1.52 (0.89–2.61) | 0.124 | ||
| Chemotherapy | 1.16 (0.59–2.26) | 0.667 | 2.21 (1.44–3.38) | <0.001 | 1.62 (1.06–2.47) | 0.024 | ||
CI, confidence interval; ITP, immune thrombocytopenic purpura.